Clinical Trials

Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy

Location:

Jacksonville,  FL,  Rochester,  MN

Trial status:

Open for Enrollment

Why is this study being done?

In this study, we propose to evaluate a novel, thermal therapy and feedback system (Visualase® Thermal Therapy System) as an alternative to surgical resection for the treatment of focal lesional epilepsy in patients that are considered high risk surgical candidates. This system includes the FDA-cleared Visualase Cooled Laser Applicator System (VCLAS), which allows delivery of laser energy while the patient is being imaged by an MRI unit. The Visualase® System works via real-time MR thermal imaging (MRTI) to provide information on the thermal dose delivered to the target, resulting in a more precise and controlled delivery which has heretofore not been possible with previous non-image guided laser technology. We hypothesize that the Visualase system can be used in patients refractory to medication therapy in a minimally invasive procedure to destroy epileptogenic focal lesions in the brain.

Who is eligible to participate?

Inclusion Criteria:

- Age 18 years or older at entry to protocol.

- History of MRI lesional-related epilepsy for at least one year.

- Failure to respond to more than 2 AEDs at adequate dose and duration.

- Candidate for resective epilepsy surgery.

- Considered healthy enough to undergo surgery with general anesthesia.

- The patient has given written informed consent after the nature of the study and alternative treatment options have been explained.

- Must have 3 months of seizure frequency recorded prior to procedure.

Exclusion Criteria:

- Presence of any non-MRI compatible implanted electronic device.

- Presence of a metallic prosthetic or implant including artificial hips, knees, joints, or rods and screws.

- Active Major depression

- History of Suicide attempts

- History of Non-Epileptic Behavioral Spells

Last updated: 04/25/2013

NCT ID: NCT01703143

IRB Number:10-007909